Preface. I: Multiple Risk Factors in Population. 1. Lipid Risk Factors and the Regression of Atherosclerosis; A. M. Gotto Jr. 2. Multiple Risk Factors: What is Next? M. Higgins, C. Lenfant 3. Multiple Risk Factors in Northern Italy; G. A. Feruglio, D. Vanuzzo, G. Cesana, M. Ferrario on behalf of the MONICA- Friuli and MONICA-Brianza Study Groups. 4. Long-Term Associations between Hemostatic Variables and Ischemic Heart Disease; T. W. Meade. 5. Cardiovascular Gene Therapy: Possibilities and Realities; V. J. Dzau, R. Morishita, G. H. Gibbons. 6. Triglycerides and Coronary Heart Disease: An Update; M. H. Criqui. II: Lipids and Lipoproteins. 7. Factors Controlling Lipoprotein Metabolism; E. Sehayek, S. Eisenberg. 8. Apolipoproteins in the Treatment of Vascular and Nonvascular Disease; C. R. Sirtori. 9. Explorations of Postprandial Lipids in a Case of Homozygous APO B45.2; B. Jacotot, A. Piolot, M. Ayraut-Jarrier, N. Lemort, C. Martin, S. Braschi, F. Yen, B. Bihain. 10. Apolipoprotein E Binding and Hepatic Lipase-Mediated Catabolism Make Alternate Pathways in the Metabolism of Intermediate Lipoprotein Particles: Observation in Patients with Hepatic Lipase Deficiency; A. Yamamoto, Y. Ikeda, Z. Tsutsumi, A. Mori, A. Takagi, M. Tsushima. III: Critical Aspects of Vascular Protection of New Dihydropyridine Calcium Antagonists. 11. New Aspects of the Pharmacology of Dihydropyridine Calcium Antagonists; T. Godfraind, O. Feron, N. Morel, S. Salomone, M. Wibo. 12. Membrane Interaction of Lipophilic Dihydropyridines as New Mechanisms for VascularProtection; G. Gaviraghi, D. Trist. 13. Mechanisms of Free Radical Oxidations and Vascular Damage: Protective Effect of Dihydropyridines; F. Ursini. 14. Lipophilic Dihydropyridines: New Opportunities for Prevention of Atherosclerosis; R. Paoletti. 15. Clinical Trial Design and Noninvasive Atherosclerosis Endpoints for Studying Lipophilic Dihydropyridines; M. G. Bond, M. Mercuri, R. Arens, F. Gianfrate for the ELSA Collaborative Research Group. IV: N-3 Fatty Acids and Cardiovascular Risk Factors. 16. The Biological Roles of n-e Fatty Acids: Metabolic and Nutritional Aspects; C. Galli. 17. Effect of Supplementation with Moderate Doses of n-3 Fatty Acid Ethyl Esters to Hypertriglyceridemic Patients on Lipid and Hemostatic Variables; E. Tremoli, S. Colli, P. Maderna, S. Eligini, E. Stragliotto, P. Risé, F. Pazzucconi, C. R. Sirtori, C. Galli. 18. Long-Lasting Inhibition of Platelet Aggregation Following a Relatively Short-Course Administration of n-3 Fatty Acid Ethyl Esters; A. M. Cerbone, T. Cusano, E. Tremoli, C. Galli, F. Cirillo, A. Coppola, E. Stragliotto, A. Amoriello, V. Marottoli, G. Vecchione, G. Di Minno. V: Diabetes. 19. Insulin Resistance and Cardiovascular Risk Factors in Noninsulin-Dependent Diabetes Mellitus; K. G. M. M. Alberti. 20. Glucose as a Risk Factor for Atherosclerosis; R. Bucala, A. Cerami. 21. Dyslipidemia in NIDDM: New Insights; M.-R. Taskinen, M. Syvänne, S. Lahdenperä. 22. Diabetes and Cardiovascular Risk: Epidemiological Aspects; S. M. Haffner. 23. Rational Treatment of the Plurimetabolic Syndrome'; A
